Those familiar with cloud services companies usually think of the high-flying salesforce.com (CRM US) as the standard-bearer for success. Salesforce is the largest provider of cloud-based customer relationship management (CRM) software services in the world, and its expansive and well-integrated ecosystem covers e-commerce, marketing services, analytics and more, helping it best serve customers across diverse industries. In the life sciences industry, however, there’s another player – Veeva Systems (VEEV US) – that’s established itself as the top player, and it’s done so in an interesting way.
2018 was a tough year for bond investors. US Total Bond Market (represented by BND US ETF) returned -0.1% and Emerging Markets Bonds (represented by EMB US ETF) returned -5.5%.
Looking at last year’s returns, a logical question arose: what should we do with our exposure to Emerging Markets (EM) Bonds? Should we keep our allocation unchanged, reduce or eliminate it and replace it with US Treasuries?
The logical chain of thought dictates that investors require higher rates of return for higher levels of risk. If the FED is increasing rates, increased rates provide an option to have investments in safe government bonds with higher yields than before. It raises the required rate of return for taking higher risks, thus investors require higher yields on riskier assets for example EM bonds. It should also lead to a higher spread between EM Bonds and US Treasuries.
Our weighted average return in December was -8.26%. Since 2015, we have generated a net return of +27.65%.
In terms of investment strategy performance, our weighted average net returns for December were (a) -0.11% for conservative strategies, (b) -5.83% for balanced strategies, and (c) -13.14% for aggressive strategies.
December was the worst month for the S&P 500 index (-9.18%) since February of 2009, capping off a year that generated negative returns in all asset classes except short-term US government debt.